Interpreting FLAURA2 for Sequencing Strategies in in EGFR-Mutant NSCLC

Heather Wakelee, MD, and Helena Yu, MD, discuss how findings from FLAURA2 (NCT04035486), including subsequent therapy outcomes, are influencing clinical decision-making. They consider whether post-progression outcomes are reassuring and how early exposure to chemotherapy may impact later treatment options. The discussion also addresses whether upfront intensification has shifted clinical comfort and raises the question of potential overtreatment in certain patient populations.